Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer

Gao, Jianwei; Qiu, Xiangyu; Li, Xinying; Fan, He; Zhang, Fang; Lv, Tangfeng; Song, Yong

doi:10.1016/j.bbrc.2018.02.114

Cited by 73 publications

(50 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was shown that T cell immunoglobulin-and mucin-domain-containing molecule 3 (Tim-3) is the next-generation immune checkpoint that can be activated by its ligand Galectin-9 to negatively regulate the antitumor immune response. Exosomal proteins, especially 5 Journal of Immunology Research exosomal TIM-3 and Galectin-9, could be potential biomarkers for non-small-cell lung cancer [113].…”

Section: Tex In Cancer Immunotherapiesmentioning

confidence: 99%

Tumor-Derived Exosomes in Immunosuppression and Immunotherapy

Olejarz

Dominiak

Żołnierzak

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Tumor-derived exosomes (TEX) are involved in cancer development, metastasis, and disease progression. They can modulate angiogenesis to elevate the malignant degree of tumor cells. TEX carry immunosuppressive factors affecting the antitumor activities of immune cells. Tumor cells as well as immune cells secrete immunologically active exosomes which affect intercellular communication, antigen presentation, activation of immune cells, and immune surveillance. Cell proliferation and immune response suppression create a favorable microenvironment for tumor. TEX can inhibit immune cell proliferation, induce apoptosis of activated CD8+ Teffs, suppress NK cell activity, interfere with monocyte differentiation, and promote Treg as well as MDSC expansion. Exosomes of microenvironment cells may also contribute to the development of drug resistance in cancer therapy. An important role of TEX in modulating the sensitivity of tumor cells to immunotherapy is a promising area of research to make the cancer therapy more successful.

show abstract

Section: Tex In Cancer Immunotherapiesmentioning

confidence: 99%

Tumor-Derived Exosomes in Immunosuppression and Immunotherapy

Olejarz

Dominiak

Żołnierzak

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Moreover, TIM-3 expression on CD4+ TILs correlated with poor patient prognosis in non-small-cell lung cancer. Gao et al [66] then reported that plasma exosomal TIM-3 was significantly higher in that cancer than in healthy samples, and high TIM-3 levels positively correlated with several malignant parameters, including larger tumor size, advanced stages and increased lymph node and distant metastases. in advanced melanoma and colorectal cancer [51,52].…”

Section: Tim-3 and Lung Cancermentioning

confidence: 98%

Immunoregulation effects of TIM-3 on tumors

Sheng

Han

2019

neo

View full text Add to dashboard Cite

Cancer poses a serious threat to human health and its increasing incidence has made it one of the most common causes of death. Immune factors affect in vivo tumor cell survival and expansion, and cancer patients have obvious cell immune dysfunction and low anti-tumor immunity. TIM-3 can be widely expressed in a variety of immune cells and it affects both innate and adaptive immune response by regulating the function of immune cells, thus affecting tumor occurrence and development. This paper focuses on the TIM-3 regulation of immune cells, and its expression and mechanism in patients with liver, gastric and prostate cancers in order to explore its regulatory mechanism in tumor immunity and provide new ideas and targets for tumor immunotherapy.

show abstract

“…Actually, PD-L1 carried by EVs was investigated for its role as biomarker and functional inducer of PD-1mediated immunosuppression (87)(88)(89)(90). TIM3 and GAL9 bound to EVs were proposed as prognostic biomarkers in NSCLC patients (91).…”

Section: Evs As Mir Shuttles and Mdsc Modulatorsmentioning

confidence: 99%

microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy

et al. 2020

View full text Add to dashboard Cite

Immunotherapy with immune checkpoint inhibitors can achieve long-term tumor control in subsets of patients. However, its effect can be blunted by myeloid-induced resistance mechanisms. Myeloid cells are highly plastic and physiologically devoted to wound healing and to immune homeostasis maintenance. In cancer, their physiological activities can be modulated, leading to an expansion of pro-inflammatory and immunosuppressive cells, the myeloid-derived suppressor cells (MDSCs), with detrimental consequences. The involvement of MDSCs in tumor development and progression has been widely investigated and MDSC-induced immunosuppression is acknowledged as a mechanism hindering effective immune checkpoint blockade. Small non-coding RNA molecules, the microRNAs (miRs), contribute to myeloid cell regulation at different levels, comprising metabolism and function, as well as their skewing to a MDSC phenotype. miR expression can be indirectly induced by cancer-derived factors or through direct miR import via extracellular vesicles. Due to their structural stability and their presence in body fluids miRs represent promising predictive biomarkers of resistance, as we recently found by investigating plasma samples of melanoma patients undergoing immune checkpoint blockade. Dissection of the miR-driven involved mechanisms would pave the way for the identification of new druggable targets. Here, we discuss the role of these miRs in shaping myeloid resistance to immunotherapy with a special focus on immunosuppression and immune escape.

show abstract

Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer

Cited by 73 publications

References 23 publications

Tumor-Derived Exosomes in Immunosuppression and Immunotherapy

Tumor-Derived Exosomes in Immunosuppression and Immunotherapy

Immunoregulation effects of TIM-3 on tumors

microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy

Contact Info

Product

Resources

About